First Fiduciary Investment Counsel Inc. Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First Fiduciary Investment Counsel Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 1.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 98,579 shares of the company’s stock after selling 1,415 shares during the quarter. Johnson & Johnson makes up 4.0% of First Fiduciary Investment Counsel Inc.’s holdings, making the stock its 4th largest holding. First Fiduciary Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $16,104,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of JNJ. Red Wave Investments LLC raised its position in Johnson & Johnson by 2.0% in the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after purchasing an additional 59 shares during the period. Argus Investors Counsel Inc. raised its position in Johnson & Johnson by 0.6% in the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after purchasing an additional 61 shares during the period. Alta Capital Management LLC raised its position in Johnson & Johnson by 0.4% in the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after purchasing an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC raised its position in Johnson & Johnson by 0.7% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after purchasing an additional 62 shares during the period. Finally, Mason & Associates Inc raised its position in Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the period. Institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The disclosure for this sale can be found here. Insiders sold 277,886 shares of company stock valued at $48,550,549 in the last ninety days. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 1.5 %

JNJ opened at $169.76 on Thursday. The stock has a market capitalization of $443.83 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 3.28 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business has a fifty day moving average price of $176.30 and a 200 day moving average price of $171.39. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.60 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. StockNews.com initiated coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Morgan Stanley dropped their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Citigroup lifted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Finally, Sanford C. Bernstein dropped their price objective on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.